The BTK inhibitor ibrutinib is a promising new therapeutic strategy for glioma, blocking the proliferation, migration and invasion properties and inducing apoptosis and autophagy of glioma cells, targeting the Akt/mTOR pathway (Wang et al., 2017). This evidence concerns the gene MTOR and central nervous system cancer.